a, a N Clinical Trials

A listing of a, a N clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 11844 clinical trials
Featured trial
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis and other myeloid neoplasms.

cell transplantation
myelofibrosis
  • 0 views
  • 19 Sep, 2022
  • 20 locations
Featured trial
A Study Evaluating Safety and Tolerability and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

<a href="https://myelofibrosisresearch.com/CW" target="_blank">www.myelofibrosisresearch.coma>


There are 4 parts to this study for which the primary objectives are to evaluate

bone marrow procedure
chronic myelomonocytic leukemia
leukemia
essential thrombocythemia
stem cell transplantation
  • 49 views
  • 17 Sep, 2022
  • 36 locations
Featured trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kδ Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis

The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.

  • 13 views
  • 20 Sep, 2022
  • 129 locations
Featured trial
PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

This study consists of 2 parts. Part 1 of the study is conducted to evaluate the efficacy, safety, and tolerability of two doses of K0706 compared to placebo in subjects with early Parkinson's Disease who are not receiving dopaminergic therapy. Part 2 is an optional long term extension study for …

early parkinson's
  • 20 views
  • 04 Oct, 2022
  • 72 locations
Featured trial
A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kδ Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib

The purpose of the study is to compare the efficacy and safety of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis who have suboptimal response while receiving ruxolitinib monotherapy.

  • 6 views
  • 19 Sep, 2022
  • 153 locations
Featured trial
A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304) (POD1UM-304)

The purpose of this study is to assess the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metastatic squamous and nonsquamous non-small cell lung cancer (NSCLC).

  • 0 views
  • 17 Sep, 2022
  • 117 locations
Featured trial
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) (FIGHT-209)

. This study consists of 3 cohorts, Cohorts A, B, and C, and will enroll approximately 82, 82, and 25 participants into each cohort, respectively. Participants will receive pemigatinib 13.5 mg QD on a 2

oligodendroglioma
FGFR1
recurrent tumor
astrocytoma
ccnu
  • 3 views
  • 17 Sep, 2022
  • 21 locations
Featured trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma (InMIND)

This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical benefit

follicular lymphoma
marginal zone lymphoma
rituximab
lenalidomide
  • 5 views
  • 21 Sep, 2022
  • 183 locations
Featured trial
Study to evaluate HZN-825 in patients with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

(administered once daily (QD) or twice daily (BID)), or a placebo regimen for 52 weeks.Participants who complete all study visits may be eligible to enter a 52-week extension study where

raynaud's phenomenon
raynaud's syndrome
MRSS
diffuse cutaneous systemic sclerosis
rheumatism
  • 10 views
  • 16 Sep, 2022
  • 55 locations
Featured trial
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects

Our team of medical professionals is evaluating an investigational drug that is designed to slow the progression of Alzheimer’s disease. The study drug, ALZ-801, is a tablet that is taken twice

mild dementia
mini-mental state examination
dementia
apolipoprotein e
  • 76 views
  • 20 Sep, 2022
  • 79 locations